1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,624 | 0,630 | 14:28 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SYNTHAVERSE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 56,24 | -0,21 % | Novonesis Q1 Net Profit Rises, Net Sales Up 7% Organically; Backs FY26 Outlook | BRUSSELS (dpa-AFX) - Novonesis A/S (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B) Tuesday said that its first quarter net profit rose from last year, helped by good performances by the Food... ► Artikel lesen | |
| GENMAB | 245,10 | +1,20 % | Genmab Reports Q2 Worldwide Net Trade Sales Of DARZALEX | NEW BRUNSWICK (dpa-AFX) - Genmab A/S (GMAB) announced that worldwide net trade sales of DARZALEX, including sales
of the subcutaneous product, as reported by J&J were $4.207 billion in the... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,940 | +1,81 % | Arbutus, Genevant File International Lawsuits Against Pfizer, BioNTech | NEW YORK CITY (dpa-AFX) - Arbutus Biopharma (ABUS), and its licensee, Genevant Sciences - a unit of Roivant Sciences (ROIV)), announced the filing of three international lawsuits seeking to... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,218 | +3,81 % | Die Zukunft der Ernährung: Große Chancen für MustGrow und K+S! Wie geht es nach dem Absturz bei Evotec weiter? | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Die globale Lebensmittelversorgung steht vor einem tiefgreifenden Wandel. Eine wachsende Weltbevölkerung, die Erderwärmung und strengere... ► Artikel lesen | |
| VERICEL | 42,200 | +4,98 % | Vericel Corporation: Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026 | ||
| MOLECULIN BIOTECH | 2,150 | +0,47 % | Moleculin Biotech, Inc.: Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment | Access the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive... ► Artikel lesen | |
| FAETH THERAPEUTICS | 27,960 | -0,82 % | Citizens initiates Faeth Therapeutics stock at outperform, $51 target | ||
| BIOXCEL THERAPEUTICS | 0,818 | +7,07 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| REGENXBIO | 9,250 | +2,37 % | Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments | ||
| ZEVRA THERAPEUTICS | 10,750 | +1,90 % | Zevra Therapeutics Announces Publication of Positive MIPLYFFA Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) | BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living... ► Artikel lesen | |
| AKEBIA | 1,093 | -4,17 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Strengthens Vafseo (vadadustat) Patent Portfolio | CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 8,350 | -2,91 % | Fennec Pharmaceuticals Inc.: Fennec Announces Results of Annual Meeting | RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 12,840 | +4,01 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China | SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in... ► Artikel lesen | |
| REVANCE THERAPEUTICS | - | - | Revance taps dancer Julianne Hough to choreograph social media push for Botox rival | ||
| CARTESIAN THERAPEUTICS | 7,050 | +0,71 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases | WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans... ► Artikel lesen |
SYNTHAVERSE SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,632 Euro und damit +0,16 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNTHAVERSE SA finden Sie auf Wallstreet Online.